Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
|Articles|June 1, 2002
- Pharmaceutical Technology-06-02-2002
- Volume 26
- Issue 6
Microencapsulation of Paracetamol by Various Emulsion Techniques Using Cellulose Acetate Phthalate
Author(s)Ali Nokhodchi, PharmD, PhD
Three methods for microencapsulating paracetamol using cellulose acetate phthalate as the coating agent revealed significant differences in terms of drug content, microcapsule size, and drug release rate.
Advertisement
Articles in this issue
over 24 years ago
Excipient GMP Quality Standards: One is Enoughover 24 years ago
The IPEC-Americas Excipient Master File Guideover 24 years ago
Technology Advances Anticounterfeiting Optionsover 24 years ago
Calibration of Lyophilization Pressure Gaugesover 24 years ago
Drug Shortages Reveal GMP Concernsover 24 years ago
Outsourcing Outlookover 24 years ago
Optimizing Cross-Organizational Team Performance and Managementover 24 years ago
Screening for Counterfeit Drugs Using Near-Infrared Spectroscopyover 24 years ago
Building on Tradition: Integrating the Links of ExpertiseAdvertisement
Related to this article
FDA final guidance defines when companion app output counts as drug labeling and when device-connected or standalone apps belong in prescribing information.
Science, circularity, regulation, and technology are reshaping how the industry develops packaging for medicines.
Panelists on PharmTech AI Pulse Check debate SURPASS, a new digital-twin trial program, regulatory acceptance, and the data-cleanup burden it will create.
Roche-Hansoh, Merck KGaA-Silence, and Lilly-METiS deals show how ADCs, siRNA, and lipid nanoparticles reshape demands on CMC and manufacturing teams.
Germany is home to several prominent pharma companies and more than 1000 innovative biotechs.
Boyang Wang of Immortal Dragons explains how FDA's Expedited IND Pilot and QRIs could compress sequential first-in-human steps as China's Decree 818 raises the pace.
The deadline to comment on FDA's generative AI paper is Oct 19, 2026. We explain why professionals in pharma manufacturing should weigh in.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Germany’s Medical Biotechnology Sector is Flourishing
2
Formulation Strategies for Next-Generation Multiagonists
3
PharmTech AI Pulse Check: Why Pharma Should Weigh In on FDA's Generative AI Paper
4
MASH and Cardiomyopathy Targets: Why AstraZeneca Chose insitro’s AI
5